The Pharma Data

MARCH 18, 2022

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab 1. 2 The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone.1

Antibody 52

Antibody HR Trials Dermatology 52

pharmaphorum

MAY 4, 2021

Sonelokimab is a single-domain antibody – a fragment of an antibody that can bind specifically to an antigen with high affinity. It is a potential competitor to Novartis’ blockbuster Cosentyx (secukinumab) and clinical evidence for its use in dermatology and rheumatology is already stacking up.

Licensing 52

Licensing Licensing Dermatology Antibody 52

pharmaphorum

SEPTEMBER 16, 2022

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being.

Dermatology 100

Dermatology Trials Drugs Development 100

pharmaphorum

JANUARY 18, 2022

It’s an amazing opportunity to put their knowledge and experience in dermatology, together with our expertise in molecular glues to accelerate drug discovery to treat skin diseases. It also builds on complementary core expertise of each partner to facilitate research and drug development.”.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

Pharmaceutical Technology

FEBRUARY 18, 2023

Gevokizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase I program in Metastatic Renal Cell Carcinoma. XOMA 052 is a potent human engineered IgG2 monoclonal antibody, binds to IL-1 beta, a pro-inflammatory cytokine. The company offers generic medicines and biosimilars through Sandoz.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

pharmaphorum

OCTOBER 1, 2021

Further details from the study – which involved four doses of either a high or low dose of the antibody over a 12-week period and a clinical assessment at 16 weeks – were presented at the EADV dermatology congress this week.

Drugs 103

Drugs Antibody Dermatology Trials 103

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

The Pharma Data

NOVEMBER 8, 2020

Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. Dermatology shows resilience in Europe and initial signs of recovery in the US.

Dermatology 52

Dermatology Sales Marketing Production 52

pharmaphorum

SEPTEMBER 30, 2022

. “SIM0278 has great potential to treat a broad spectrum of immunological diseases, and we expect that its development will allow us to reinforce our biologic pipeline and our leading position in medical dermatology,” said Almirall’s chief scientific officer Karl Ziegelbauer in a statement. Last year, Merck & Co paid $1.85

Licensing 52

Licensing Licensing Dermatology Drugs 52

XTalks

SEPTEMBER 22, 2022

The novel, selective monoclonal antibody spesolimab behind Spevigo reduces flares in individuals by inhibiting interleukin-36 (IL-36) signalling. Waldman Department of Dermatology. GPP occurs in individuals with specific gene variations as it is a genetic disease , and variations in the genes IL36RN and AP1S3 are known to cause it.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Dermatology 52

The Pharma Data

JANUARY 12, 2021

Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

MARCH 27, 2022

More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting.

Dermatology 52

Dermatology Medicine Antibody Protein 52

The Pharma Data

AUGUST 16, 2021

Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial.

Trials 40

Trials Dermatology Bioavailability Medicine 40

The Pharma Data

DECEMBER 30, 2020

billion acquisition of immuno-oncology company Forty Seven and its lead asset, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). It began in May with the $4.9 Magrolimab targets CD47. Most Read Today.

Antibody 52

Antibody Allergies Branding Dermatology 52

The Pharma Data

MAY 15, 2023

Safety results through 24 weeks were generally consistent with the known safety profile of Dupixent in its approved dermatology indication. About Dupixent Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant.

Medicine 40

Medicine Trials Dermatology FDA Approval 40

pharmaphorum

SEPTEMBER 2, 2022

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in the US.

Drugs 105

Drugs Antibody FDA Approval Trials 105

XTalks

AUGUST 14, 2024

The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. Monoclonal antibody therapy has been found to have fewer side effects when compared to immunosuppressant drugs.

Drug Delivery Systems 97

Drug Delivery Systems Dermatology Drug Delivery Antibody 97

XTalks

AUGUST 2, 2024

Nemolizumab is a monoclonal antibody that targets IL-31, a cytokine responsible for many atopic dermatitis symptoms. These trials reveal nemolizumab’s potential to significantly improve key aspects of atopic dermatitis, including skin lesions, itch and sleep disturbance, in both adolescent and adult patients with moderate-to-severe cases.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Licensing 52

The Pharma Data

MARCH 28, 2022

Boehringer Ingelheim announced today new data from the pivotal Effisayil™ 1 trial presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston. trial investigator and Chair, Department of Dermatology at The University of Alabama School of Medicine. had clear/almost clear skin. About spesolimab.

Dermatology 52

Dermatology Trials Contract Manufacturing Medicine 52

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics.

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

pharmaphorum

MAY 31, 2022

PN is among a clutch of additional indications driven by type 2 inflammation that could account for upwards of $2 billion of that total, although if approved Dupixent may not have long on the market before it faces competition.

Sales 116

Sales Drugs Antibody Regulation 116

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

The Pharma Data

AUGUST 17, 2021

About JEMPERLI (dostarlimab-gxly) JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. The collaboration has resulted in three monospecific antibody therapies that have progressed into the clinic. Immune-Mediated Pneumonitis.

FDA Approval 52

FDA Approval Antibody DNA Hormones 52

pharmaphorum

APRIL 26, 2021

The drug is a nanobody, a molecule around one-tenth the size of a regular antibody derived from camelid species such as the llama. Proponents say they can offer greater stability, smaller size, higher potency, and lower production or synthesis costs compared to conventional monoclonal antibodies.

Antibody 52

Antibody Drugs Marketing Licensing 52

pharmaphorum

AUGUST 16, 2021

billion to take control of lebrikizumab’s developer Dermira last year after the antibody showed promising results in phase 2b trials, and has been waiting for the results of the phase 3 trials to see if that was a good move. Lilly shelled out $1.1

Antibody 52

Antibody Trials Marketing Drugs 52

XTalks

AUGUST 7, 2024

Up until this year, AbbVie’s anti-inflammatory monoclonal antibody Humira (adalimumab) reigned as the world’s best-selling drug for the past several years. This includes Bristol Myers Squibb’s Sotyktu (deucravacitinib), which received US Food and Drug Administration (FDA) approval in 2022.

FDA Approval 52

FDA Approval Genetics Antibody Drugs 52

pharmaphorum

DECEMBER 24, 2021

The antibody given as a single intravenous dose was compared to placebo in the 53-subject Effisayil-1 study, which involved people presenting with a GPP flare including high or very high density of pustules on the skin.

Trials 103

Trials Medicine Antibody Drugs 103

The Pharma Data

JUNE 7, 2022

1-2 Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin-13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R?1/IL-4R? Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

The Pharma Data

JANUARY 24, 2021

All participants randomized to receive either 4,200 mg of bamlanivimab, Lilly’s neutralizing antibody, or placebo. oncolytic virus (VVcopTK-RR-) and engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody and the human GM-CSF cytokine. Non-COVID-19-Related. BT-001 is based on the patented Invir.IO

Trials 52

Trials Allergies In-Vitro Antibody 52

pharmaphorum

OCTOBER 22, 2021

PN is among a clutch of additional indications that could account for upwards of $2 billion of that total.

Trials 105

Trials Sales Antibody Drugs 105

pharmaphorum

JANUARY 6, 2023

As Dr Shao-Lee Lin, founder and CEO of ACELYRIN, commented: “The acquisition of ValenzaBio adds additional programmes to our portfolio, such as lonigutamab.”.

Trials 59

Trials Marketing Protein Antibody 59

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs 69

Drugs Immune Response Allergies Sales 69

The Pharma Data

JULY 11, 2021

Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin in Berlin, Germany. TAKHZYRO is a fully human monoclonal antibody that specifically binds and decreases plasma kallikrein activity. All antibody titres were low. Markus Magerl, M.D., About TAKHZYRO ® (lanadelumab).

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

The Pharma Data

APRIL 13, 2022

“I’m pleased that TAKHZYRO has met these key objectives and I look forward to Takeda sharing further insights with the HAE community in the near future,” said Dr. Marcus Maurer, Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin, Germany and principal investigator of SHP643-301.

Dermatology 52

Dermatology Allergies Genetics Antibody 52

The Pharma Data

MARCH 28, 2022

The focus of the event is on Dupixent ® (dupilumab), a key growth driver, and Sanofi’s rapidly advancing pipeline, highlighting dermatological, respiratory and gastrointestinal diseases as priority therapeutic areas. Sanofi has raised the Dupixent sales peak ambition to more than €13 billion.

Medicine 52

Medicine Sales Clinical Development Development 52

The Pharma Data

AUGUST 1, 2021

Saphnelo is a first-in-class type I interferon receptor antibody and the only new medicine in over a decade for patients with systemic lupus erythematosus . Saphnelo Saphnelo (anifrolumab) is a fully human monoclonal antibody that binds to subunit 1 of the type I IFN receptor, blocking the activity of type I IFNs.

Trials 52

Trials Clinical Development Antibody Medicine 52

The Pharma Data

MARCH 15, 2022

Fasenra Fasenra (benralizumab) is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of blood and tissue eosinophils in most patients via apoptosis (programmed cell death). 2 The trial is expected to read out in the second half of 2023.

Trials 52

Trials Medicine Licensing Licensing 52